Search
Find a recruiting study
7,120 recruiting studies with US sites, from the official ClinicalTrials.gov registry (refreshed Oct 26, 2026). No sign-up needed.
Most recently updated studies · page 83 of 297
- RecruitingPhase 2/Phase 3
Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)
Thryv Therapeutics, Inc.
- Location
- Scottsdale, AZ + 6 other US sites
- Eligibility basics
- Ages 15+
- RecruitingPhase 2/Phase 3
A Study of Buntanetap in Participants With PD
Annovis Bio Inc.
- Location
- Birmingham, AL + 26 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 3
A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome
Kaken Pharmaceutical
- Location
- Charleston, SC
- Eligibility basics
- Ages 2+
- RecruitingPhase 3
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
Dompé Farmaceutici S.p.A
- Location
- Jacksonville, FL + 7 other US sites
- Eligibility basics
- Ages 10–65
- RecruitingPhase 1/Phase 2
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Tr1X, Inc.
- Location
- La Jolla, CA + 7 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
Athos Therapeutics Inc
- Location
- Miami, FL + 3 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study in Adults With Geographic Atrophy
Sitala Bio LTD
- Location
- Erie, PA + 1 other US site
- Eligibility basics
- Ages 60+
- RecruitingPhase 1/Phase 2
A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
JCR Pharmaceuticals Co., Ltd.
- Location
- Oakland, CA
- Eligibility basics
- Up to age 5
- RecruitingPhase 2
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
AstraZeneca
- Location
- Phoenix, AZ + 3 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 3
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
Novartis Pharmaceuticals
- Location
- Salt Lake City, UT
- Eligibility basics
- Ages 2–100
- Recruiting
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
ReGelTec, Inc.
- Location
- Birmingham, AL + 13 other US sites
- Eligibility basics
- Ages 22–85
- RecruitingPhase 3
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
AstraZeneca
- Location
- Aurora, CO + 1 other US site
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Novo Nordisk A/S
- Location
- Los Angeles, CA + 8 other US sites
- Eligibility basics
- Ages 2+
- RecruitingPhase 3
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Takeda
- Location
- Hot Springs, AR + 16 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
Optinose US Inc.
- Location
- Orange, CA + 18 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 1
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
UCB Biopharma SRL
- Location
- Santa Monica, CA + 5 other US sites
- Eligibility basics
- Ages 18+ · Women only
- RecruitingPhase 4
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Neurocrine Biosciences
- Location
- Bryant, AR + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
AstraZeneca
- Location
- Fullerton, CA + 2 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Vertex Pharmaceuticals Incorporated
- Location
- Montgomery, AL + 26 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Study of ALK-001 on the Progression of Stargardt Disease
Alkeus Pharmaceuticals, Inc.
- Location
- Phoenix, AZ + 11 other US sites
- Eligibility basics
- Ages 8–45
- RecruitingPhase 4
ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)
Novartis Pharmaceuticals
- Location
- New York, NY
- Eligibility basics
- Ages 2–100
- RecruitingPhase 1
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
CRISPR Therapeutics AG
- Location
- Hialeah, FL + 7 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
Alnylam Pharmaceuticals
- Location
- Orange, CA + 5 other US sites
- Eligibility basics
- Ages 16–45 · Women only
- RecruitingPhase 1/Phase 2
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
AbbVie
- Location
- Irvine, CA + 10 other US sites
- Eligibility basics
- Ages 50–90
Data source: deploy-time snapshot of the ClinicalTrials.gov API. How we list studies